New oral drugs in older patients: a review of idarubicin in elderly patients

被引：26

作者：

Crivellari, D

Lombardi, D

Spazzapan, S

Veronesi, A

Toffoli, G

机构：

[1] Ctr Riferimento Oncol, Dept Med Oncol, I-33081 Aviano, PN, Italy

[2] CRO, Expt & Clin Pharmacol Unit, Aviano, PN, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2004年 / 49卷 / 02期

关键词：

oral idarubicin; elderly breast cancer patients; oral anthracyclines;

D O I：

10.1016/S1040-8428(03)00120-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

引用

页码：153 / 163

页数：11

共 88 条

[1]

Abe O, 1998, LANCET, V352, P930

[2]

ARCAMONE F, 1976, CANCER TREAT REP, V60, P829

[3]

BANNING JW, 1987, CANCER CHEMOTH PHARM, V19, P207

[4]

BASTHOLT L, 1987, CANCER TREAT REP, V71, P451